CR
Cresco Labs Inc.
CRLBF · OTC
$0.75 +2.67% (+$0.02)
1M -10.86%
Market Cap $265.5M
P/E Ratio -
Div. Yield -
ROE 28.27%
Bulios Fair Price
$0.66
11.9% downside
Current Price
$0.75
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CRLBF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
79 /100
Cheap P/B 0.74x
EV/EBITDA 7.92x
P/FCF 26.18x
Growth
0 /100
Declining Book val. growth 18.47%
Rev. growth 7.48%
FCF growth N/A
Profitability
37 /100
Moderate Op. margin 9.83%
Gross margin 48.41%
FCF margin 1.56%
Quality
19 /100
Poor ROA 8.19%
ROIC 6.02%
Asset turnover 0.52x
Debt
25 /100
High Int. coverage 0.83x
Debt/Equity 1.65x
Net debt/EBITDA 5.37x
Stability
35 /100
Moderate EPS volatility 78.52%
Beta 1.72x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CRLBF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Charles Bachtell
Employees
2,900
Headquarters
Chicago
Upcoming events
05 NOV
Earnings
Upcoming earnings report